» Articles » PMID: 20845284

Diffuse Plexiform Neurofibroma of the Back: Report of a Case

Overview
Journal Hawaii Med J
Date 2010 Sep 17
PMID 20845284
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Neurofibromatosis type 1 is an autosomal dominant disorder affecting the ras proto-oncogene. It is characterized by the overgrowth of nervous tissue and skin discoloration. While it is associated with a variety of phenotypic presentations, it is the plexiform variant that is particular concerning, as it can become extremely disfiguring and has a propensity for malignant degeneration. A case of a Pacific Islander with a large plexiform type 1 neurofibroma is presented. The patient was ultimately treated with surgical resection, negative pressure wound therapy, and split-thickness skin grafting with good results. A review of the literature concerning the diagnosis and treatment of neurofibromatosis is included.

Citing Articles

[Emergency management and perioperative strategies for intra-tumoral hemorrhage in neurofibromatosis type 1-related giant plexiform neurofibroma].

Zhu B, Xiao Y, Liao R, Zhao H, Xu X, Zhang Y Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2024; 38(10):1180-1185.

PMID: 39433490 PMC: 11522541. DOI: 10.7507/1002-1892.202406074.


Case report: Remarkable efficacy of negative-pressure wound therapy in giant lower extremity elephantiasis neuromatosa for vascularization, skin grafting, and fluid control.

Hasibuan L, Putri A, Pramono G Int J Surg Case Rep. 2024; 116:109428.

PMID: 38428057 PMC: 10944093. DOI: 10.1016/j.ijscr.2024.109428.


Molecular profiles of different PD-L1 expression in patients with esophageal squamous cell carcinoma.

Zhao S, Hu X, Zhou P, Li A, Chen L, Wang D Cancer Biol Ther. 2023; 24(1):2256927.

PMID: 38032149 PMC: 10515684. DOI: 10.1080/15384047.2023.2256927.


Familial left cervical neurofibromatosis 1 with scoliosis: A case report.

Mu X, Zhang H, Shen Y, Yang H World J Clin Cases. 2021; 9(29):8839-8845.

PMID: 34734064 PMC: 8546810. DOI: 10.12998/wjcc.v9.i29.8839.


Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.

Haworth K, Arnold M, Pierson C, Choi K, Yeager N, Ratner N Oncotarget. 2017; 8(47):82037-82048.

PMID: 29137242 PMC: 5669868. DOI: 10.18632/oncotarget.18301.


References
1.
Ferrari A, Bisogno G, Macaluso A, Casanova M, DAngelo P, Pierani P . Soft-tissue sarcomas in children and adolescents with neurofibromatosis type 1. Cancer. 2007; 109(7):1406-12. DOI: 10.1002/cncr.22533. View

2.
Yohay K . Neurofibromatosis types 1 and 2. Neurologist. 2006; 12(2):86-93. DOI: 10.1097/01.nrl.0000195830.22432.a5. View

3.
Lammert M, Friedman J, Kluwe L, Mautner V . Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch Dermatol. 2005; 141(1):71-4. DOI: 10.1001/archderm.141.1.71. View

4.
Korf B . Malignancy in neurofibromatosis type 1. Oncologist. 2000; 5(6):477-85. DOI: 10.1634/theoncologist.5-6-477. View

5.
Babovic-Vuksanovic D, Ballman K, Michels V, McGrann P, Lindor N, King B . Phase II trial of pirfenidone in adults with neurofibromatosis type 1. Neurology. 2006; 67(10):1860-2. DOI: 10.1212/01.wnl.0000243231.12248.67. View